Show MeAcyclovir IV administration is the intravenous delivery of the antiviral acyclovir, given as a one-hour infusion every 8 hours (5 mg/kg) or every 8 to 12 hours at higher doses (10 mg/kg) for herpes simplex, varicella-zoster, and herpes encephalitis. It requires dose adjustment for kidney function, generous hydration, and slow infusion to prevent acyclovir-induced kidney injury. The drug is not given as a rapid push. Most treatment courses run 7 to 21 days depending on the infection. This article covers the mechanism, the exact dosing table, the infusion timeline, and the mistakes that cause harm.
How Acyclovir IV Works Inside the Cell
Acyclovir is a guanosine analog, meaning it mimics one of DNA's four building blocks. On its own it is nearly inert. It only becomes active after three sequential phosphorylation steps, and the first step is performed by a viral enzyme called thymidine kinase. This is the mechanism that makes the drug selective: cells infected by herpes simplex virus (HSV) or varicella-zoster virus (VZV) carry the viral kinase, while uninfected human cells largely do not.
The viral kinase converts acyclovir to acyclovir monophosphate roughly 30 to 100 times faster than cellular enzymes can. Host cell kinases then add two more phosphates. The finished acyclovir triphosphate competes with natural guanosine triphosphate at the viral DNA polymerase. When it is incorporated into the growing DNA chain, the missing 3-hydroxyl group stops further elongation. The chain terminates.
Two consequences follow from this mechanism. First, acyclovir triphosphate has roughly 30 to 50 times greater affinity for viral DNA polymerase than for the human enzyme. Second, it is a weak chain terminator of host DNA, which is why toxicity is relatively low at standard doses. In plain terms: the drug is a fake DNA brick that only the virus is tricked into using.
The intracellular half-life differs by virus. In HSV-infected cells, acyclovir triphosphate persists about 10 to 20 hours, which supports every-8-hour dosing. VZV-infected cells are less efficient at phosphorylating the drug, which is why VZV requires higher doses (10 mg/kg) than HSV (5 mg/kg).
The Dosing Table: Weight, Indication, and Kidney Function
Dose depends on three variables at once: the infection being treated, the patient's weight, and creatinine clearance (CrCl). Standard dosing uses ideal body weight or adjusted body weight in obese patients, not total body weight, because acyclovir distributes mainly into lean tissue and excess fat does not require additional drug.
| Indication | Dose (adults, normal renal function) | Interval | Typical duration |
|---|---|---|---|
| HSV mucocutaneous (moderate-severe) | 5 mg/kg | Every 8 hours | 5-7 days |
| HSV encephalitis | 10 mg/kg | Every 8 hours | 14-21 days |
| VZV (herpes zoster, hospitalized) | 10 mg/kg | Every 8 hours | 7 days |
| Varicella (severe, immunocompromised) | 10 mg/kg | Every 8 hours | 7-10 days |
| HSV prophylaxis (immunocompromised) | 5 mg/kg | Every 8 or 12 hours | Variable |
For a 70 kg adult with normal kidneys, 5 mg/kg equals 350 mg per dose, or 1,050 mg per day. At 10 mg/kg, the daily total is 2,100 mg. The maximum single dose is generally capped at 10 mg/kg or 800 mg, whichever is lower in some protocols, because higher exposures drive crystal nephropathy without added antiviral benefit.
Renal dosing is where most errors occur. For CrCl 25 to 50 mL/min, the interval stretches from every 8 hours to every 12 hours at the same 5 to 10 mg/kg dose. For CrCl 10 to 25 mL/min, the interval becomes every 24 hours. For CrCl below 10 mL/min, the dose is halved and given every 24 hours. These figures come from the FDA-approved labeling and are consistent across the major renal dosing references. The critical reconciliation: interval extension and dose reduction are not interchangeable. Below CrCl 25, you do both. Above CrCl 25, you extend the interval only.
Acyclovir Infusion Timeline: From Order to Steady State
Acyclovir IV has a predictable time course that most patients and many clinicians do not fully appreciate. The following table lays out the key milestones.
| Time point | What happens | Why it matters |
|---|---|---|
| Hour 0 | Dose ordered, weight and CrCl verified | Wrong weight is the top dosing error |
| Hour 0-1 | Drug diluted in at least 100 mL of fluid, typically normal saline | Concentration above 7 mg/mL raises phlebitis risk |
| Hour 1-2 | One-hour infusion at controlled rate, often via pump | Faster infusion raises crystal risk |
| Hour 2-3 | Peak plasma concentration reached at end of infusion | Peak levels drive both efficacy and nephrotoxicity |
| Hour 2-8 | Distribution; roughly 15-30% protein bound | Drug enters tissues and cerebrospinal fluid |
| Hour 8-10 | About 60-90% excreted unchanged in urine | Renal clearance dominates elimination |
| Hour 8 (next dose) | Second dose given if kidneys allow | Half-life in normal kidneys is 2-3 hours |
| Day 2-3 | Steady state reached in normal renal function | Prolonged in kidney impairment |
| Day 7-21 | Course completion depending on indication | Encephalitis needs the full 14-21 days |
In normal renal function, the elimination half-life is about 2.5 to 3.3 hours, so steady state is reached within roughly 12 to 16 hours of starting therapy. In patients with CrCl under 10 mL/min, the half-life can stretch to 20 hours or more, which is why dosing every 24 hours is not arbitrary but pharmacologically grounded.
Why Hydration and Infusion Speed Matter So Much
The most feared acute complication of acyclovir IV is crystal nephropathy. Acyclovir is poorly water-soluble. When it concentrates in the urine beyond its solubility limit, it precipitates as needle-shaped crystals in the renal tubules. This blocks urine flow and can cause acute kidney injury within 24 to 48 hours of starting therapy. The reported incidence in hospitalized patients is roughly 12 to 48% depending on hydration status and infusion rate, which is far higher than most package inserts suggest.
Two variables control this risk. The first is urine flow. If the patient is well hydrated, urine dilutes the drug below its precipitation threshold. The second is infusion rate. Rapid infusion spikes plasma concentration, which in turn spikes the amount filtered into the tubule per unit time. A one-hour infusion is the standard precisely because it balances convenience against crystal risk.
The numbers are striking. In one widely cited series, patients who received acyclovir by rapid bolus had a significantly higher rate of kidney injury than those who received a one-hour infusion, even at identical total daily doses. The practical rule: infuse over at least 60 minutes, and give at least 1 mL of fluid per mg of drug (so a 700 mg dose needs 700 mL of hydration, spread across the day, not in one bolus).
In plain terms: the drug is safe if the kidneys keep flushing it out fast enough. Slow the flush, and the drug turns to sand.
Common Mistakes and Edge Cases
The most common error is using total body weight in a patient with obesity. A 140 kg patient given 10 mg/kg would receive 1,400 mg, well above the tolerated ceiling, because fat does not distribute the drug. Use ideal or adjusted body weight.
A second error is failing to reduce frequency in kidney impairment. A patient with CrCl 20 mL/min given every-8-hour dosing accumulates drug, and the neurotoxicity risk rises sharply. Acyclovir neurotoxicity presents as confusion, hallucinations, myoclonus, or seizures. It is more common in dialysis patients and in those with CrCl under 25 mL/min, and it can be mistaken for the viral encephalitis being treated.
A third edge case is the obese patient on renal replacement therapy. In intermittent hemodialysis, acyclovir is removed by the dialyzer, so doses must be given after each session, not before. In continuous renal replacement therapy, clearance is closer to normal, and dosing often follows the CrCl 25 to 50 mL/min interval.
A fourth is the neonatal and pediatric patient. Pediatric doses are weight-based and often higher per kilogram (for example, 20 mg/kg every 8 hours for neonatal HSV), because drug clearance is faster in neonates. The adult 5 to 10 mg/kg figures do not transfer directly to infants.
Finally, consider the patient on concomitant nephrotoxins. Combining acyclovir with amphotericin, aminoglycosides, or high-dose NSAIDs multiplies kidney injury risk. In these patients, hydration and monitoring become more aggressive, not less.
Acyclovir IV Versus Oral and Other Antivirals
The choice between IV and oral acyclovir depends on how much drug reaches the virus. Oral acyclovir has poor bioavailability, roughly 15 to 30% of the dose. The IV route achieves plasma levels 5 to 10 times higher, which is why encephalitis, disseminated VZV, and severe HSV in immunocompromised patients require the IV form.
| Route or drug | Bioavailability | Typical use | Key limitation |
|---|---|---|---|
| Acyclovir IV | 100% (by definition) | Encephalitis, severe VZV, immunocompromised HSV | Requires admission, hydration, renal monitoring |
| Acyclovir oral | 15-30% | Mild HSV, zoster in healthy adults | Low and variable absorption |
| Valacyclovir oral | 54-60% (prodrug of acyclovir) | Zoster, HSV suppression | Not equivalent to IV for severe disease |
| Foscarnet IV | 100% | Acyclovir-resistant HSV/VZV | Nephrotoxicity, electrolyte disturbances |
| Ganciclovir IV | 100% | Cytomegalovirus | Different virus target, marrow suppression |
The comparison that matters clinically: valacyclovir oral reaches acyclovir exposure roughly 3 to 5 times higher than oral acyclovir, but still below IV levels. For a patient who can swallow and absorb, valacyclovir is often sufficient for shingles. For a patient who cannot, IV acyclovir remains the standard.
If HSV is resistant to acyclovir (thymidine kinase-deficient strains), the drug will not work regardless of dose. Resistance is more common in immunocompromised patients and after prolonged exposure. In that setting, foscarnet is the switch.
What to Actually Do Before and During an Acyclovir IV Course
Practical actions, in order:
- Verify weight using ideal or adjusted body weight, and calculate CrCl with the Cockcroft-Gault equation before ordering. Recalculate daily in unstable patients.
- Dilute the dose to a concentration of 7 mg/mL or less, and infuse over at least one hour using a pump. Never give as a rapid push.
- Hydrate to maintain urine output of at least 1 mL/kg/hour, and ensure at least 1 mL of fluid per mg of drug across the day.
- Check serum creatinine at baseline and every 24 to 48 hours during therapy. A rise of 0.3 mg/dL or more warrants dose review.
- Watch for neurotoxicity in any patient with CrCl under 25 mL/min. Confusion or myoclonus should prompt an immediate dose check and drug-level consideration.
- Treat the full duration for encephalitis (14 to 21 days), even after clinical improvement, because relapse carries high mortality.
Do not stop therapy early in HSV encephalitis just because the fever resolves. The virus can rebound, and the mortality of untreated or under-treated encephalitis exceeds 50%.
Limits of the Evidence and Open Questions
Several aspects of acyclovir IV practice rest on convention rather than high-quality trials. The one-hour infusion standard, for example, is based largely on pharmacokinetic modeling and observational nephrotoxicity data, not on randomized comparisons of infusion durations. The exact hydration volume needed to prevent crystals in every patient is not established, and the 1 mL per mg rule is a reasonable heuristic rather than a proven threshold.
The relationship between acyclovir plasma levels and neurotoxicity is also incompletely characterized. Some patients develop confusion at levels within the usual therapeutic range, while others tolerate higher exposures. Routine therapeutic drug monitoring is not standard, though it is used in dialysis patients and in suspected toxicity.
Resistance testing is underused. In a patient who fails to improve on IV acyclovir after 7 to 10 days, thymidine kinase genotyping can distinguish treatment failure from drug resistance. This is a hypothesis-level recommendation in many settings, but it is gaining support as resistant HSV becomes more common in immunocompromised populations.
Finally, the long-term renal outcomes after a single episode of acyclovir crystal nephropathy are not well studied. Most patients recover kidney function, but whether subclinical injury accumulates with repeated courses is unknown. For now, the best defense remains the same: correct dose, slow infusion, and generous hydration.